Floatz logo

rc48

CDK12 Gene Mutation

Tianjin Medical University Second Hospitalantibody_drug_conjugatePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the CDK12 Gene Mutation cohort.

Asset / SponsorPhaseRating
Abemaciclib
University of California, Davis
Phase 2CCC
Niraparib
University of California, Davis
Phase 2CCC
Envafolimab
Tianjin Medical University Second Hospital
Phase 1/2CCC

Same molecule, other indications

rc48 is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
RC48Dormant
CCC
Indicative ·
53 / 100
View asset →
ERBB2 Mutation-Related TumorsDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →